Study with brain tissue from human epilepsy patients confirms that brain cells express CombiGene’s candidate drug CG01
CombiGene has, in collaboration with Associate Professor David Woldbye at University of Copenhagen and Professor Merab Kokaia at Lund University, carried out a so-called ”human expression study”, i.e. a study using brain tissue from human epilepsy patients. A similar study with positive results has previously been carried out when neuropeptide Y was directly applied to human tissue of the same kind. Neuropeptide Y is the neurotransmitter that CG01 expresses in the brain via genes. This is, however, the first study testing the candidate drug, CG01, in human tissue.
Read more >>
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.